Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends.

Cancers (Basel) · 2022 · PMC9817525 · PMID 36612047

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

A strong trend in favor of OS benefit was also observed; the 12 month OS rate for T-DXd was 94.1% vs. 85.9% for T-DM1 (HR 0.56; p 0.007172), non-statistically significant since OS outcomes were not yet mature.

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.